Skip to main content
. Author manuscript; available in PMC: 2018 Nov 2.
Published in final edited form as: Pharmacotherapy. 2017 Nov 2;37(11):1366–1373. doi: 10.1002/phar.2032

Table 2.

Effect of Clinical and Genetic Predictors on Warfarin Dose Requirements by Kidney Transplant Status

Variable β % Dose Change
(95% CI)		 p Value
Clinical and demographic variables only (Model 1; R2 =21.1%)a
Intercept   1.848
African-American   0.177 19.3 (14.0, 25.0) <0.0001
Age (per 10 years) −0.076 −7.3 (−8.7, −5.9) <0.0001
Female −0.137 −12.8 (−16.7, −8.8) <0.0001
Body mass index (kg/m2)   0.009   0.9 (0.6, 1.2) <0.0001
Congestive heart failure −0.071 −6.9 (−11.6, −1.9)   0.0077
Kidney functionb −0.064 −6.2 (−9.4, −2.8)   0.0004
Amiodarone −0.211 −19.0 (−24.7, −13.0) <0.0001
Transplant status −0.202 −18.3 (−27.0, −8.6) 0.0004
Clinical, demographic, and genetic variables (Model 2; R2 = 42.3%) c
Intercept   2.182
African-American −0.063 −6.1 (−11.2, −0.7)   0.0262
Age (per 10 years) −0.075 −7.2 (−8.6, −5.9) <0.0001
Female −0.133 −12.4 (−16.3, −8.4) <0.0001
Body mass index (kg/m2)   0.009   0.9 (0.6, 1.2) <0.0001
Congestive heart failure −0.088 −8.4 (−13.0, −3.5)   0.0009
Kidney functionb −0.054 −5.2 (−8.5, −1.9)   0.0027
Amiodarone −0.246 −21.8 (−27.2, −16.1) <0.0001
CYP2C9*2d −0.195 −17.7 (−22.2, −13.0) <0.0001
CYP2C9*3d −0.423 −34.5 (−39.3, −29.3) <0.0001
CYP2C9*5, *6, *11e −0.161 −14.9 (−28.5, 1.3)   0.0689
VKORC1d −0.308 −26.5 (−29.2, −23.7) <0.0001
CYP4F2d   0.038   3.9 (−0.1, 8.1)   0.0564
rs12777823 −0.092 −8.8 (−12.9, −4.5)   0.0001
Transplant status −0.210 −18.9 (−27.8, −8.9)   0.0004

β denotes parameter estimates.

CI = confidence interval.

a

The referent patient was a 40-year-old, European-American man without a kidney transplant, with an estimated glomerular filtration rate (eGFR) > 60 ml/min/1.73 m2, body mass index (BMI) 25 kg/m2, with no congestive heart failure (left ventricular ejection fraction >55%), and not taking amiodarone.

b

Kidney function was categorized into 3 groups based on eGFR: ≥ 60, 30–59, and < 30 ml/min per 1.73 m2. This was included as an ordinal variable in the model with eGFR ≥ 60 ml/min/1.73 m2 serving as the reference group.

c

The referent patient was a 40-year-old, European-American man without a kidney transplant with an eGFR > 60 ml/min/1.73 m2, BMI 25 kg/m2, with no congestive heart failure (left ventricular ejection fraction >55%), not taking amiodarone, and not possessing variants in CYP2C9*2, CYP2C9*3, CYP4F2, and VKORC1; and CYP2C9*5, *6, and *11 together; and rs12777823.

d

CYP2C9*2, CYP2C9*3, CYP4F2, and VKORC1 were included as additive; 0 if no variants; 1 if heterozygous and 2 if homozygous for the variant allele.

e

CYP2C9*5, *6, and *11 together, and rs12777823 were categorized as 0 if no variants and 1 if heterozygous or homozygous for the variant allele.